Mar 15, 2024

Sun JinboChina
Type of disease: lung cancer
Treatment plan: Combo Knife
Survival period: more than 3 years
If I didn't tell him, no one would know that this 80-year-old man, who looked like he was taking a leisurely stroll in the garden, was a lung cancer patient on the second day after minimally invasive treatment with Kangbo Knife.

Grandpa Sun is 81 years old this year. He lives in Haizhu District, Guangzhou. He is an authentic Guangzhou native. After retiring many years ago, he has been entertaining his grandchildren at home and sharing a family relationship. Unfortunately, during an examination at a tertiary hospital in October 2021, he was diagnosed with small cell lung cancer in the right lung. The family members were shocked after hearing the news, and a pair of children rushed home anxiously to find a hospital for their father and find a suitable anti-cancer method.
After all, the old man was old, and the children were unwilling for their father to accept overly aggressive treatment methods and finally chose chemotherapy to fight the tumor. In order not to hinder his children, Grandpa Sun also actively fought against cancer and bravely and successfully withstood the side effects of 5 rounds of chemotherapy. Unfortunately, the tumor on the right chest wall has shrunk after chemotherapy, but it still has a residual size of about 4CM*1.8CM. In order to solve this stubborn tumor, the doctor in charge suggested that he combine radiotherapy, but the patient and his family refused. Later, through the recommendation of an acquaintance, the family learned about our hospital, and after many considerations, they decided to let Grandpa Sun come to our hospital to receive minimally invasive cancer treatment.

Considering that Grandpa Sun is over 80 years old and has underlying diseases such as hypertension, he has undergone five rounds of chemotherapy and there is still a residual tumor of about 4CM*1.8CM. Based on the treatment demands of patients and their families, the MDT team led by Dai Wenyan, director of the First Department of Oncology in our hospital, unanimously believed that Kangbo ablation was more suitable for patients. Then on March 30, I, Director Dai Wenyan, performed the Kangbo Knife ablation on Grandpa Sun. After the patient is given local anesthesia, under the guidance of CT, an ablation probe of about 2 mm is precisely punctured into the tumor. After two switching between extreme low and high temperatures from -196°C to 80°C, the chest wall tumor is completely ablated.
"This minimally invasive surgery is also very challenging. The patient is 81 years old, and the tumor has invaded the pleura. He is worried about adverse reactions such as obvious pain and pneumothorax." Director Dai Wenyan explained, "So we also made sufficient preparations before the operation. The entire operation went very smoothly. The patient was basically pain-free during the operation, and the blood loss was about 10 milliliters. There was no pneumothorax during or after the operation."

After the operation, Grandpa Sun felt that his breathing was much smoother. "The day of my operation went very well. I don't cough much anymore. I eat well and sleep well. Now when I have nothing to do, I just walk around the ward as a walk. I will be discharged and go home in two days!" Grandpa Sun said with a smile during the ward rounds.
There are many cancer patients who cannot undergo traditional surgery or radiotherapy and chemotherapy due to physical reasons. The emergence of minimally invasive cancer treatment has given them more choices and new hope. Elderly cancer patients like Grandpa Sun are typical examples.
Kangbo Knife is a first-generation cryotherapy technique that is suitable for more than 80% of solid tumors. It can be performed alone or combined with surgery or radiotherapy and chemotherapy, and is highly flexible. And according to the literature, a large number of neoantigens can be produced in the body after Kangbo knife cryotherapy, which increases the effect of immunotherapy on tumor patients and opens up a blue ocean for future combination immunotherapy!
